NEW YORK, Dec. 20 - GeneProt has delivered six synthetic proteins to Novartis Pharma as part of the companies' year-old research partnership, GeneProt said on Thursday.
Delivering the synthetic proteins, generated using technology licensed from Gryphon Sciences, marks the first publicly announced transfer of drug candidates to Novartis under the collaboration, signed in October 2000. Of the six proteins, Novartis has selected three for further investigation, the companies said.
One of these is active in modulating the differentiation of cell types, and another is a tachykinin splice variant that has a specific role in the peripheral nervous system. The two companies did not disclose information on the other four proteins. Novartis retains rights to develop all six proteins into therapeutics, diagnostic markers, or drug targets.
"With GeneProt now having demonstrated the ability to provide us with proteomics-based leads on a regular basis, we are looking forward to exciting developments and new pharmaceutical therapies over the coming years," said Jörg Reinhardt, head of development for the Basel, Switzerland-based biotech firm.
In October, GeneProt announced plans to move its corporate headquarters to North Brunswick, NJ, from the Chicago area and build a second proteomics facility near its new headquarters, in addition to the company's flagship facility in Geneva. Novartis is currently GeneProt's only disclosed pharma customer.